RXi Pharmaceuticals (NASDAQ:RXII) is scheduled to announce its earnings results after the market closes on Tuesday, August 14th. Analysts expect the company to announce earnings of ($0.59) per share for the quarter.
RXi Pharmaceuticals (NASDAQ:RXII) last posted its quarterly earnings results on Thursday, May 10th. The biotechnology company reported ($0.90) EPS for the quarter. The company had revenue of $0.02 million for the quarter. On average, analysts expect RXi Pharmaceuticals to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.
RXi Pharmaceuticals opened at $1.64 on Friday, Marketbeat.com reports. The stock has a market capitalization of $6.47 million, a P/E ratio of -0.39 and a beta of 1.31. RXi Pharmaceuticals has a 12 month low of $1.29 and a 12 month high of $7.70.
About RXi Pharmaceuticals
RXi Pharmaceuticals Corporation, a biotechnology company, focuses on discovering and developing immuno-oncology therapeutics to treat cancer. The company's lead product candidate is RXI-109, an sd-rxRNA that reduces the expression of connective tissue growth factor, a critical regulator of several biological pathways involved in fibrosis, including scar formation in the skin and eye.
See Also: Growth Stocks
Receive News & Ratings for RXi Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RXi Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.